Drug intelligence / Profile preview

erythromycin + tretinoin

Development stage
Unknown
Lead developer
Almirall
Modality
Small Molecules
Administration
Topical
01

Overview

Aknemycin Plus Lösung is a topical combination therapy containing the macrolide antibiotic erythromycin and the retinoid tretinoin. It is indicated for the treatment of various forms of acne vulgaris, including both non-inflammatory comedonal acne and inflammatory papulopustular acne, particularly in patients with oily (seborrheic) skin. Erythromycin acts as an antibacterial agent that inhibits protein synthesis in acne-associated bacteria such as *Cutibacterium acnes*, thereby reducing bacterial colonization and local inflammation. Tretinoin, a vitamin A derivative, promotes skin cell turnover, decreases the cohesiveness of follicular epithelial cells, and facilitates the extrusion of comedones, preventing new blockages from forming. The formulation is delivered as a cutaneous solution with an integrated applicator pad, allowing for direct and hygienic application to the affected skin areas.

Brand names
Aknemycin PlusAknemycin Plus LösungAknemycin Plus cutaneous solutionE-SolEfasol GelStievamycin
Other names
tretinoin + erythromycin
02

Targets

RARA (Retinoic acid receptor alpha)Bacterial 50S ribosomal subunitCRABP2 (Cellular retinoic acid-binding protein 2)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)

Beyond the preview

Go deeper on erythromycin + tretinoin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythromycin + tretinoin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call